Literature DB >> 24798049

The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease.

Salvatore Petta1, Ester Vanni, Elisabetta Bugianesi, Vito Di Marco, Calogero Cammà, Daniela Cabibi, Lavinia Mezzabotta, Antonio Craxì.   

Abstract

BACKGROUND & AIMS: The accuracy of noninvasive tools for the diagnosis of severe fibrosis in patients with nonalcoholic fatty liver disease(NAFLD) in clinical practice is still limited. We aimed at assessing the diagnostic performance of combined noninvasive tools in two independent cohorts of Italian NAFLD patients.
METHODS: We analysed data from 321 Italian patients(179 Sicilian-training cohort, and 142 northern Italy-validation cohort) with an histological diagnosis of NAFLD. Severe fibrosis was defined as fibrosis ≥ F3 according to Kleiner classification. The APRI, AST/ALT, BARD, FIB-4, and NFS scores were calculated according to published algorithms. Liver stiffness measurement(LSM) was performed by FibroScan. Cut-off points of LSM, NFS and FIB-4 for rule-in or rule-out F3-F4 fibrosis were calculated by the reported formulas.
RESULTS: In the Sicilian cohort AUCs of LSM, NFS, FIB-4, LSM plus NFS, LSM plus FIB-4, and NFS plus FIB-4 were 0.857, 0.803, 0.790, 0.878, 0.888 and 0.807, respectively, while in the northern Italy cohort the corresponding AUCs were 0.848, 0.730, 0.703, 0.844, 0.850, and 0.733 respectively. In the training cohort, the combination of LSM plus NFS was the best performing strategy, providing false positive, false negative and uncertainty area rates of 0%,1.1% and 48% respectively. Similar results were obtained in the validation cohort with false positive, false negative and uncertainty area rates of 0%,7.3% and 40.8%.
CONCLUSIONS: The combination of LSM with NFS, two complementary, easy-to-perform, and widely available tools, is able to accurately diagnose or exclude the presence of severe liver fibrosis, also reducing of about 50-60% the number of needed diagnostic liver biopsies.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  LSM; NAFLD; NFS

Mesh:

Substances:

Year:  2014        PMID: 24798049     DOI: 10.1111/liv.12584

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  32 in total

Review 1.  Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries.

Authors:  Hilmar K Lückhoff; Frederik C Kruger; Maritha J Kotze
Journal:  World J Hepatol       Date:  2015-05-28

2.  A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosis.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Sanjiv Mahadeva
Journal:  Hepatol Int       Date:  2014-12-06       Impact factor: 6.047

3.  Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.

Authors:  Toshihide Shima; Kyoko Sakai; Hirohisa Oya; Takayuki Katayama; Yasuhide Mitsumoto; Masayuki Mizuno; Yoshihiro Kanbara; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2019-09-19       Impact factor: 7.527

4.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

Review 5.  Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.

Authors:  Jia-Zhen Zhang; Jing-Jing Cai; Yao Yu; Zhi-Gang She; Hongliang Li
Journal:  Gene Expr       Date:  2019-04-22

Review 6.  Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet?

Authors:  Naim Alkhouri; Ariel E Feldstein
Journal:  Metabolism       Date:  2016-02-02       Impact factor: 8.694

7.  The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Elliot B Tapper; Tracy Challies; Imad Nasser; Nezam H Afdhal; Michelle Lai
Journal:  Am J Gastroenterol       Date:  2016-03-15       Impact factor: 10.864

8.  Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography.

Authors:  Elliot B Tapper; Neil Sengupta; M G Myriam Hunink; Nezam H Afdhal; Michelle Lai
Journal:  Am J Gastroenterol       Date:  2015-08-25       Impact factor: 10.864

9.  Fibroscan-Based Score to Predict Significant Liver Fibrosis in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Wei-Yu Kao; I-Wei Chang; Chi-Long Chen; Chien-Wei Su; Sheng Uei Fang; Jui-Hsiang Tang; Chun-Chao Chang; Yu-Jia Chang; Weu Wang
Journal:  Obes Surg       Date:  2020-04       Impact factor: 4.129

10.  MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.

Authors:  Jinho Jung; Rohan R Loomba; Kento Imajo; Egbert Madamba; Sanil Gandhi; Ricki Bettencourt; Seema Singh; Carolyn Hernandez; Mark A Valasek; Cynthia Behling; Lisa Richards; Katie Fowler; Claude B Sirlin; Atsushi Nakajima; Rohit Loomba
Journal:  Gut       Date:  2020-11-19       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.